390 related articles for article (PubMed ID: 34712243)
1. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
Front Immunol; 2021; 12():757836. PubMed ID: 34712243
[TBL] [Abstract][Full Text] [Related]
2. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
Jiang H; Fu D; Bidgoli A; Paczesny S
Front Immunol; 2021; 12():761448. PubMed ID: 34675938
[TBL] [Abstract][Full Text] [Related]
3. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation.
Gao MG; Hong Y; Zhao XY; Pan XA; Sun YQ; Kong J; Wang ZD; Wang FR; Wang JZ; Yan CH; Wang Y; Huang XJ; Zhao XS
Front Immunol; 2021; 12():720354. PubMed ID: 34539656
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.
Sheng L; Mu Q; Wu X; Yang S; Zhu H; Wang J; Lai Y; Wu H; Sun Y; Hu Y; Fu H; Wang Y; Xu K; Sun Y; Zhang Y; Zhang P; Zhou M; Lai B; Xu Z; Gao M; Zhang Y; Ouyang G
Front Immunol; 2020; 11():1534. PubMed ID: 32849519
[No Abstract] [Full Text] [Related]
7. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
Kumari R; Palaniyandi S; Hildebrandt GC
Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
[TBL] [Abstract][Full Text] [Related]
8. Novel Insights Into the Mechanism of GVHD-Induced Tissue Damage.
Ara T; Hashimoto D
Front Immunol; 2021; 12():713631. PubMed ID: 34512636
[TBL] [Abstract][Full Text] [Related]
9. Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature.
Biernat MM; Urbaniak-Kujda D; Dybko J; Kapelko-Słowik K; Prajs I; Wróbel T
J Int Med Res; 2020 Jun; 48(6):300060520925693. PubMed ID: 32527171
[TBL] [Abstract][Full Text] [Related]
10. T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?
Campe J; Ullrich E
Front Immunol; 2021; 12():806529. PubMed ID: 35069590
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation.
Yazdandoust E; Hajifathali A; Roshandel E; Zarif MN; Pourfathollah AA; Parkhideh S; Mehdizadeh M; Amini-Kafiabad S
Transpl Immunol; 2023 Jun; 78():101836. PubMed ID: 37037266
[TBL] [Abstract][Full Text] [Related]
12. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
14. Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice.
Wu Y; Bastian D; Schutt S; Nguyen H; Fu J; Heinrichs J; Xia C; Yu XZ
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1195-204. PubMed ID: 25846718
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
Front Immunol; 2019; 10():295. PubMed ID: 30891031
[TBL] [Abstract][Full Text] [Related]
16. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
[TBL] [Abstract][Full Text] [Related]
17. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
18. IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
Lu Y; Giver CR; Sharma A; Li JM; Darlak KA; Owens LM; Roback JD; Galipeau J; Waller EK
Blood; 2012 Jan; 119(4):1075-85. PubMed ID: 22130799
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk Between Intestinal Microbiota Derived Metabolites and Tissues in Allogeneic Hematopoietic Cell Transplantation.
Fujiwara H
Front Immunol; 2021; 12():703298. PubMed ID: 34512627
[TBL] [Abstract][Full Text] [Related]
20. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
[Next] [New Search]
